The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors

Transfusion Medicine

Volumn 23, Issue 5, 2013, Pages 358-366

  O'Brien, S F ^a,b   Goldman, M ^a,b   Scalia, V ^a   Yi, Q L ^a,b   Fan, W ^a   Xi, G ^a   Dines, I R ^a   Fearon, M A ^a,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epidemiology; HTLV; Risk factors

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BLOOD TRANSFUSION; CANADA; FEMALE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; DONOR SELECTION; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; MIDDLE AGED; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; BLOOD DONORS; BLOOD TRANSFUSION; CANADA; DONOR SELECTION; FEMALE; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84884729807     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12057     Document Type: Article

References (28)

1. Carneiro-Proietti, A.B., Catala-Soares, B.C., Castro-Costa, C.M. et al. (2006) HTLV in the Americas: challenges and perspectives. Pan American Journal of Public Health, 19, 44-53.
2. Davison, K.L., Dow, B., Barbara, J.A., Hewitt, P.E. & Eglin, R. (2009) The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002-2006. Transfusion Medicine, 19, 24-34.
3. Goldman, M., Patterson, L. & Long, A. (2006) Recent Canadian experience with targeted hepatitis C virus lookback. Transfusion, 46, 690-694.
4. Hewitt, P.E., Davison, K., Howell, D.R. & Taylor, G.P. (2013) Human T lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction. Transfusion[Epub ahead of print; DOI: 10.1111/trf.12105].
5. Kaplan, J.E., Osame, M., Kubota, H., Igata, A., Nishitani, H., Maeda, Y., Khabbaz, R.F. & Janssen, R.S. (1990) The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. Journal of Acquired Immune Deficiency Syndromes, 3, 1096-1101.
6. Kleinman, S., Swanson, P., Allain, J.P. & Lee, H. (1993) Transfusion transmission of human T-lymphotropic virus types I and II: serological and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion, 33, 14-18.
7. Laperche, S., Worms, B., Pillonel, J. & for the European Network of Transfusion Medicine Societies and the Steering Committee of the Epidemiological Surveillance of Blood Donors in France (2009) Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sanguinis, 96, 104-110.
8. Martin, J.D., Mathias, R.G., Sarin, C. & Byrne, S.E. (2002) Human T-lymphotropic virus type I and II infections in first nations alcohol and drug treatment centres in British Columbia, Canada, 1992-2000. International Journal of Circumpolar Health, 61, 98-102.
9. Murphy, E.L., Hanchard, B., Figueroa, J.P., Gibbs, W.N., Lofters, W.S., Campbell, M., Goedert, J.J. & Blattner, W.A. (1989) Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type 1. International Journal of Cancer, 43, 250-253.
10. Murphy, E.L., Figueroa, J.P., Gibbs, W.N. et al. (1991) Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. American Journal of Epidemiology, 133, 1114-1124.
11. Murphy, E.L., Watanabe, K., Nass, C.C., Ownby, H., Williams, A. & Nemo, G. (1999) Evidence among blood donors for a 30-year-old epidemic of Human T Lymphotropic Virus Type II infection in the United States. Journal of Infectious Diseases, 180, 1777-1783.
12. O'Brien, S.F., Yi, Q.-L., Fan, W., Scalia, V., Kleinman, S.H. & Vamvakas, E.C. (2007a) Current incidence and estimated residual risk of transfusion transmitted infections in donations made to Canadian Blood services. Transfusion, 47, 316-25.
13. O'Brien, S.F., Fearon, M.A., Yi, Q.-L., Fan, W., Scalia, V., Muntz, I.R. & Vamvakas, E.C. (2007b) Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion, 47, 1809-1815.
14. O'Brien, S.F., Fan, W., Xi, G. et al. (2008) Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion, 48, 902-909.
15. Okochi, K., Sato, H. & Hinuma, Y. (1984) A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: Seroconversion in recipients. Vox Sanguinis, 46, 245-253.
16. Peters, A.A., Coulthart, M.B., Oger, J.J.F., Waters, D.J., Crandall, K.A., Baumgartner, A.A., Ward, R.H. & Dekaban, G.A. (2000) HTLVI/II in British Columbia Amerindians: a seroprevalence study and sequence characterization of an HTLV type IIa isolate. AIDS Research and Human Retroviruses, 9, 883-892.
17. Prinsze, F.J. & Zaaijer, H.L. (2012) The outcome of screening for Human T-cell lymphotropic virus infection in the Netherlands. Vox Sanguinis, 102, 198-203.
18. Proietti, F.A., Caneiro-Proietti, A.B.F., Catalan-Spares, B.C. & Murphy, E.L. (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene, 24, 6058-6068.
19. Roucoux, D.F. & Murphy, E.L. (2004) The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Review, 6, 144-154.
20. Rubin, D.B. (1987) Multiple imputation for nonresponse in surveys. J. Wiley & Sons, New York.
21. Schreiber, G.B., Busch, M.P., Kleinman, S.H., Korelitz, J.J. & for the Retrovirus Epidemiology Donor Study (1996) The risk of transfusion-transmitted viral infections. The New England Journal of Medicine, 334, 1685-1690.
22. Sibbald, B. (2006) HTLV-1 virus detected in Nunavut. CMAJ News, 174, 150-151.
23. Sonoda, S., Chuan-Li, H. & Tajima, K. (2011) Ethnoepidemiology of HTLV-1 related disease: Ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Science, 102, 295-301.
24. Stienlauf, S., Yahalom, V., Schwartz, E., Shinar, E., Segal, G. & Sidi, Y. (2009) Epidemiology of human T-cell lymphotropic virus type 1 infection in blood donors, Israel. Emerging Infectious Diseases, 15, 1116-1118.
25. Stramer, S.L., Foster, G.A. & Dodd, R.Y. (2006) Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion, 46, 703-707.
26. Sullivan, M.T., Williams, A.E., Fang, C.T., Grandinetti, T., Poiesz, B.J. & Erlich, G.D. (1991) Transmission of human T-lymphotropic virus types I and II by blood transfusion: a retrospective study of recipients of blood components (1983 through 1988). Archives of Internal Medicine, 151, 2043-2048.
27. Verdonck, K., Gonzalez, E., Van Dooren, S., Vandamme, A., Vanham, G. & Gotuzzo, E. (2007) Human T-lymphotropic virus-1: recent knowledge about an ancient infection. The Lancet Infectious Diseases, 7, 266-281.
28. Zou, S., Stramer, S.L. & Dodd, R.Y. (2012) Donor testing and risk: current prevalence, incidence and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfusion Medicine Reviews, 26, 119-128.